IKNA
Ikena Oncology, Inc.
Industry
Biotechnology
Ikena Oncology, Inc., a targeted oncology company, focuses on developing medicines tailored to biomarker-defined patient groups for specific unmet needs. Its lead targeted oncology product candidate is IK-930, an oral small molecule inhibitor of the transcriptional enhanced associate domain, transcription factor in the Hippo signaling pathway. It is also developing a small molecule inhibitor program against ERK5 in the RAS signaling pathway; IK-175, an oral inhibitor of aryl hydrocarbon receptor; and IK-007, an oral selective EP4 receptor antagonist for the treatment of microsatellite stable colorectal cancer. The company was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Loading...
Open
1.66
Mkt cap
79M
Volume
37K
High
1.67
P/E Ratio
-1.33
52-wk high
2.32
Low
1.64
Div yield
N/A
52-wk low
1.22

Portfolio Pulse from Benzinga Newsdesk
August 08, 2024 | 9:21 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.